Search
for
Sort by
Research
150-180 / 1000+ resultsresearch Supplemental Materials for "No Increased Cardiovascular Hazard with Oral 5-Alpha-Reductase Inhibitors in Treatment of Androgenetic Alopecia: A TriNetX Retrospective Cohort Study"
research Reduced Prostate Cancer Risk in Patients with Androgenetic Alopecia Using 5-Alpha Reductase Inhibitors: A TriNetX Real-World Cohort Study
research Effects of finasteride, a 5 alpha-reductase inhibitor, on circulating androgens and gonadotropin secretion in hirsute women
research Effect of finasteride, a 5 alpha-reductase inhibitor, on serum gonadotropins in normal men
research The effect of finasteride, a 5 alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness
research Effect of MK-386, a novel inhibitor of type 1 5 alpha-reductase, alone and in combination with finasteride, on serum dihydrotestosterone concentrations in men
research Bladder Cancer Survival of Men Receiving 5α-Reductase Inhibitors
Men taking 5-alpha-reductase inhibitors before or after bladder cancer diagnosis had a lower risk of dying from the disease.
research Synthesis and Biological Evaluation of 4-(4-(Alkyl-and Phenylaminocarbonyl)benzoyl)benzoic Acid Derivatives as Non-steroidal Inhibitors of Steroid 5α-Reductase Isozymes 1 and 2
The compound 4c effectively inhibits the enzyme linked to hair loss.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
These medications for BPH have known risks and may have new side effects.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
These medications for BPH have known risks and may have new side effects.
research Long-term use of 5α-reductase inhibitors and the risk of male breast cancer
Taking 5α-reductase inhibitors does not significantly increase the risk of breast cancer in men.
research Novel 5α-Reductase Inhibitors: Synthesis, Structure−Activity Studies, and Pharmacokinetic Profile of Phenoxybenzoylphenyl Acetic Acids
A brominated phenoxy compound effectively inhibits a human enzyme and shows potential for clinical use.
research Synthesis, Biological Evaluation and Molecular Docking of Avicequinone C Analogues as Potential Steroid 5α-Reductase Inhibitors
Certain compounds, especially those with a propionic substituent, could potentially be new treatments for hair loss and similar disorders.
research Generation of comparative pharmacophoric model for steroidal 5α-reductase I and II inhibitors: A 3D-QSAR study on 6-azasteroids
The study created a model to help design new inhibitors for steroidal 5α-reductase enzymes.
research Macular Abnormalities Associated With 5α-Reductase Inhibitor
Using 5-alpha-reductase inhibitors, drugs for prostate issues and hair loss, may lead to eye abnormalities in men.
research Risk of rhabdomyolysis from 5-α reductase inhibitors
Starting 5-alpha reductase inhibitors does not significantly increase the risk of rhabdomyolysis in older men, but is linked to a higher risk of muscle conditions.
research Five-Alpha Reductase Inhibitor and Breast Cancer Risk in Men: A Systematic Review
Taking 5-alpha reductase inhibitors does not increase breast cancer risk in men.
research 5‐α reductase inhibitors and the risk of anaemia among men with benign prostatic hyperplasia: A population‐based cohort study
5α-reductase inhibitors do not increase anaemia risk compared to α-blockers in men with BPH.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
PDE5 inhibitors cause earlier adverse events in BPH treatment, requiring careful monitoring.
research Review: Adding α1-blockers to 5α-reductase inhibitors improves lower urinary tract symptoms in men
Combining α1-blockers with 5α-reductase inhibitors improves urinary symptoms in men.
research Faculty Opinions recommendation of Association between 5-alpha reductase inhibition and risk of hip fracture.
5-alpha reductase inhibitors do not increase hip fracture risk.
research Influencia del tratamiento con alfa bloqueantes e inhibidores de la 5 alfa reductasa en los hallazgos morfológicos e inmunohistoquímicos de la hiperplasia benigna de próstata
Finasteride treatment makes the prostate look more like a healthy one.
research Effect of Testosterone Supplementation With and Without a Dual 5α-Reductase Inhibitor on Fat-Free Mass in Men With Suppressed Testosterone Production
Testosterone's muscle-building effects do not require its conversion to DHT.
research Selective non-steroidal inhibitors of 5α-reductase type 1
Selective non-steroidal inhibitors of 5α-reductase type 1 can help treat DHT-related disorders.
research Male Breast Cancer and 5α-Reductase Inhibitors Finasteride and Dutasteride
Using finasteride or dutasteride does not increase the risk of male breast cancer.
research Benzo[c]quinolizin-3-ones: A Novel Class of Potent and Selective Nonsteroidal Inhibitors of Human Steroid 5α-Reductase 1
Benzo[c]quinolizin-3-ones are effective nonsteroidal inhibitors of human steroid 5α-reductase 1.
research Inhibitory activities of some traditional Chinese herbs against testosterone 5α-reductase and effects of Cacumen platycladi on hair re-growth in testosterone-treated mice
Certain Chinese herbs, especially Cacumen platycladi, can promote hair regrowth and reduce hair loss-related hormone levels in mice.
research Synthesis and biological evaluation of novel unsaturated carboxysteroids as human 5α-reductase inhibitors: A legitimate approach
New steroid compounds effectively inhibit 5α-reductase and may treat hair loss.
research The Impact of 5α-Reductase Inhibitor Use for Male Pattern Hair Loss on Men’s Health
Hair loss drugs may cause sexual issues and infertility in men.